Research Funding

Grant Title Grantor Amount Award Date
Lakshmi Rajagopal, PhD
Role of an ornithine rhamnolipid pigment in GBS virulence - R01 AI112619 NIH/NIAID $250,000 annual direct costs July 1, 2014 - June 30, 2019
Lisa M. Frenkel, MD
"Evaluation of mHealth strategies to optimize adherence and efficacy of PMTCT/ART" - R01 HD080460 (PI: John-Stewart) NIH $11,393 subcontract annual direct costs May 1, 2014 - April 30, 2019
Lisa M. Frenkel, MD
"A rapid point-of-treatment diagnostic assay for HIV-resistance to 1st-line ART" - R01 AI110375 NIH $250,000 annual direct costs May 1, 2014 - April 30, 2019
Lisa M. Frenkel, MD
Mechanisms of Formation and Persistence of Active HIV Reservoirs - R01 AI111806 (PI: Mullins) NIH $114,390 subcontract annual direct costs April 1, 2014 - March 31, 2019
Jane L. Burns, MD
Prevalence and Clinical Significance of S. aureus small-colony variants - HOFFMA14A0 (PI: Burns and Hoffman) Cystic Fibrosis Foundation Therapeutics $109,481 Burns annual direct costs April 1, 2014 - March 31, 2017
Timothy Rose, PhD
Point-of-care diagnosis and surveillance of known and emerging influenza viruses - R01 AI111303 NIH/NIAID $855,731 annual directs March 15, 2014 - Feb. 28, 2019
Thor A. Wagner, MD
"Mechanisms of Formation and Persistence of Active HIV Reservoirs" - R01 AI111806 (PI: Mullins) NIH $10,720 subcontract annual direct costs March 15, 2014 - Feb. 28, 2019
Lisa M. Frenkel, MD
"International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group" Virology Lab - UM1 AI106716 (PI: Aldrovandi) NIH $95,547 annual direct costs Jan. 1, 2014 - Nov. 30, 2020
Heather B. Jaspan, MD, PhD
"Intestinal microbiota, immune activation and vaccine responsiveness of the HIV-exposed infant" (Co-PI with Cameron) Canadian Institutes of Health Research $100,000 2014 - 2015
Jane L. Burns, MD
Long Term Outcomes after Eradication of Pseudomonas aeruginosa among Children Enrolled in the EPIC Clinical Trial - #CTBM100CUSNC01T (PI: Hamblett) Novartis $34,426 annual direct costs Dec. 15, 2013 - Dec. 15, 2015
Lakshmi Rajagopal, PhD
Environmental signals that regulate GBS virulence - R21 AI109222 NIH/NIAID $150,000 annual direct costs Sept. 1, 2013 - Aug. 31, 2015
Jane L. Burns, MD
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with Cystic Fibrosis - UM1 HL119073 (PI: Goss) $55,495 Burns' annual direct costs Sept. 1, 2013 - June 30, 2016
Lakshmi Rajagopal, PhD
Eukaryotic-type signaling mediates two-component regulation of GBS virulence - R56 AI070749-06A1 NIH/NIAID $247,362 annual direct costs June 11, 2013 - Dec. 31, 2014
Lisa M. Frenkel, MD
"University of Washington Center for AIDS Research" (CFAR) - P30 AI027757 (PI: Holmes) NIH $95,547 annual direct costs June 1, 2013 - May 31, 2015
Marta Bull, PhD
"University of Washington Center for AIDS Research" (CFAR) - P30 AI027757 (PI: King Holmes) NIH $11,528 subcontract annual direct costs June 1, 2013 - May 31, 2015
Janet A. Englund, MD
Clinical Significance of rhinovirus Seattle Children's Hospital Clinical Translational Research Center Dec. 20, 2012 - Sept. 30, 2013
Danielle M. Zerr, MD, MPH
Frequency and Duration of Intestinal Carriage and Bacterial Evolution Over Time in Pediatric Patients with Resistant Enterobacteriaceae Infections Children's Research Institute/Translational Research Ignition Projects Program $50,000 Dec. 12, 2012 - Sept. 30, 2013
Jane L. Burns, MD
A Phase 2, Randomized, Double Blind, Placebo-Controlled, Repeat-Dose Study of KB001 A in Subjects with Cystic Fibrosis Infected with Pseudomonas aeruginosa KaloBios Pharmaceuticals, Inc. $45,032 total direct costs Oct. 10, 2012 - Oct. 9, 2014
Danielle M. Zerr, MD, MPH
Impact of chlorhexidine bathing on reducing infections in children with cancer NIH/NCI $410,000 Aug. 1, 2012
Lakshmi Rajagopal, PhD
GBS mediated in utero fetal injury - R01 AI100989 (Co-PI with Kristina Adams Waldorf) NIH/NIAID $499,906 annual direct costs July 1, 2012 - June 30, 2017
Lisa M. Frenkel, MD
"Drug-resistance testing in Kenya to improve ART suppression of HIV replication" (PEPFAR) - R01 AI100037 NIH $695,729 annual direct costs June 3, 2012 - May 31, 2015
Janet A. Englund, MD
RSV surveillance and antibody levels in Southeast Asia PATH May 2012 - June 2014
Lisa M. Frenkel, MD
"Academic Pediatric Infectious Disease" - T32 HD007233 NIH $277,930 annual direct costs May 1, 2012 - April 30, 2017
Jane L. Burns, MD
Lab Services - Grifols Protocol# T6005-201 Grifols Therapeutics, Inc. April 10, 2012 - April 10, 2014
Scott J. Weissman, MD
Differences in infecting and colonizing Enterobacteriaceae from short-course vs standard therapy of pediatric UTI - R21AI099930 NIH/NIAID $125,000 annual DC April 1, 2012 - Feb. 28, 2015
Jane L. Burns, MD
Persistent MRSA Eradication Protocol - #PMEP11K1 (PI: Dasenbrook) CFFT $37,240 subcontract annual direct costs Jan. 1, 2012 - Dec. 31, 2014
Heather B. Jaspan, MD, PhD
"Myeloid-derived Suppressor cells (MDSC) suppress infant immune responses" (PI: Horton) (Jaspan: South African PI) NICHHD/NIH $180,000 total subcontract 2012 - 2017
Heather B. Jaspan, MD, PhD
"Innate, Adaptive and Mucosal Immune Responses in HIV-1 Exposed Uninfected Infants: A Human Model to Understand Correlates of Immune Protection" Canadian HIV Vaccine Initiative/ Canadian Institutes for Health Research $577,406 for Jaspan 2012 - 2016
Thor A. Wagner, MD
Systematic High-Throughput Screening of B-cell Repertoires to Identify Antibodies Specific for HIV-Infected Cells Bill and Melinda Gates Foundation $ Nov. 1, 2011 - April 30, 2013
Janet A. Englund, MD
New Vaccine Surveillance Network CDC Aug. 1, 2011 - July 31, 2015
Timothy Rose, PhD
Oral pathogenesis and host interactions of KSHV infection - P01 DE021954 NIH/NIDCR $993,231 + $120,000 annual directs June 7, 2011 - April 30, 2016
Serge Barcy, PhD
Oral pathogenesis and host interactions of KSHV infection - P01 DE021954 (Rose) NIH/NIDCR $993,231 annual directs June 1, 2011 - April 30, 2016
Lisa M. Frenkel, MD
"HIV-1 evolution in the female genital tract and trafficking in the blood" - R01AI091550. NIH/NIAID $254,817 annual direct costs Jan. 21, 2011 - Dec. 31, 2015
Marta Bull, PhD
"HIV-1 evolution in the female genital tract and trafficking in the blood" - R01 AI091550 (PI: Frenkel) NIH $254,817 annual direct costs Jan. 21, 2011 - Dec. 31, 2015
Heather B. Jaspan, MD, PhD
K08 "Assessing feeding practices, immune activation, and HIV risk in South African infants" NIH/NIAID $100,000 per year 2011 - 2016
Lisa M. Frenkel, MD
"Immunologic and Virologic Events in Early HIV Infection" (SEAPIP) - P01 AI057005 (Mullins). NIH $101,000 annual direct costs July 15, 2010 - June 30, 2015
Jane L. Burns, MD
Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis - P30 DK089507 (PI: Ramsey & Greenberg) NIH $25,749 Burns' annual direct costs July 6, 2010 - May 31, 2015
Danielle M. Zerr, MD, MPH
National surveillance of emerging MDR in pediatric Enterobacteriaceae infections NIH/NIAID $437,668 July 1, 2010
Scott J. Weissman, MD
Resistance and relatedness: Molecular features of Klebsiella pneumoniae as a colonizer and pathogen in pediatric patients in Seattle, WA Institute of Translational Health Sciences/UW June 3, 2010 - April 30, 2012
Scott J. Weissman, MD
National surveillance of emerging MDR in pediatric Enterobacteriaceae infections - R01 AI083413 (Co-PI with Zerr) NIH/NIAID $420,236 annual DC June 1, 2010 - May 31, 2015
Jane Burns, MD
Safety and efficacy of aztreonam Gilead Sciences Jan. 12, 2010 - Jan. 12, 2015
Thor A. Wagner, MD
HIV Persistence Despite Therapy due to Proliferation of Infected Cells Fraternal Order of Eagles Oct. 1, 2009 - Sept. 30, 2014
Jane Burns, MD
Pseudomonas aeruginosa adaptation during early cystic fibrosis infection and treatment NIH $ Sept. 11, 2009 - July 31, 2014
Danielle Zerr, MD, MPH
Impact of Daily Bathing with Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit Sage Products, Inc. $100,000.00 Sept. 1, 2009
Danielle Zerr, MD, MPH
HHV-6 and CNS disease following stem cell transplant NIH/NIAID $278,321.00 Sept. 1, 2009
Danielle Zerr, MD, MPH
National surveillance of emerging MDR in pediatric Enterobacteriaceae infections NIH/NIAID $378,005.00 Aug. 11, 2009
Timothy Rose, PhD
POC molecular method for detection of known and emerging respiratory viruses NIH/NIDCR $300,885.00 July 1, 2009
Danielle Zerr, MD, MPH
Infection Control of Keyboards (ICK) Study: A Randomized, Blinded, Multi-Center Study of Ultraviolet Light Decontamination Vioguard LLC $114,000.00 June 1, 2009
Janet A. Englund, MD
Operation of a Facility for the Study of Infectious Agents, Vaccines, and Antimicrobials NIH/ Subsite of Johns Hopkins April 7, 2009 - April 6, 2013
Lisa M. Frenkel, MD
"Low-frequency HIV-1 Drug Resistance Mutations in Primary HIV-1 Infection" - R01 AI078802 (Steckler) NIH $61,594 annual direct costs April 1, 2009 - June 30, 2015
Janet A. Englund, MD
Maternal Immunization to protect the Mother and Neonate Bill and Melinda Gates Fndn Jan. 2009 - Dec. 2014
Thor Wagner, MD
Novel microcapillary immunoassay methodology to enable point-of-care infant HIV-1 diagnosis Seattle Children’s Hospital Jan. 1, 2009
Danielle Zerr, MD, MPH
Emerging MDR in pediatric Enterobacteriaceae infections CCTR Pediatric Pilot Award $20,000.00 Dec. 1, 2008
Thor Wagner, MD
Persistent HIV-1 Replication in the Respiratory Tract Despite Antiretroviral Treatment NIH-NIAID Sept. 1, 2008 - Nov. 30, 2013
Thor A. Wagner, MD
Improving Pediatric HIV-1 Diagnostics in an Effort to Avoid Antiretroviral Treatment Failure in Tamilnadu, India Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene July 1, 2008 - June 30, 2014
Ann Melvin, MD
Bone mineral density in tenofovir-exposed infants and young children Gilead Sciences Phase4 program $47,943.00 June 23, 2008
Ann Melvin, MD
Bioethics core NIH Cooperative Agreement $1,583,701.00 June 1, 2008
Scott J. Weissman, MD
Multi-drug resistance and virulence patterns in canine and feline urinary E. coli American College of Veterinary Medicine Jan. 1, 2008 - March 31, 2011
Ann Melvin, MD
International and Domestic Pediatric and Maternal HIV Studies Coordinating Center NIH $659,107.00 Dec. 16, 2007
Lisa M. Frenkel, MD
"International and Domestic Pediatric and Maternal HIV Studies Coordinating Center" - NO1-DK-8-0001 (Melvin). NIH $11,360 annual direct costs Dec. 16, 2007 - Nov. 30, 2014
Timothy Rose, PhD
Viral and cellular factors involved in KSHV entry in cells of the oral mucosa NIH/NIDCR $1,125,000.00 Aug. 15, 2007
Timothy Rose, PhD
Herpesvirus latency and reactivation in macaque models of human disease NIH/NCRR $1,680,995.00 July 1, 2007
Lisa M. Frenkel, MD
"Occurrence and Outcome of Dual HIV-1 Infection" - R37 AI047734 (Mullins) NIH $4,987 annual direct costs July 5, 2005 - March 31, 2015
Ann Melvin, MD
Reservoirs of Drug-Resistant HIV-1 – US-India Collaborative Research Supplement NIH $58,907.00 March 1, 2005
Danielle Zerr, MD, MPH
HHV-6 and CNS disease following stem cell transplant NIH/NIAID $1,250,000.00 July 1, 2004
Jane Burns, MD
Translational Therapeutics Development Center - #GIBSON09YO (PI: Gibson) Cystic Fibrosis Foundation Therapeutics $166,400 annual direct costs April 1, 2004 - Dec. 31, 2014
Jane L. Burns, MD
Therapeutics Development Network Coordinating Center (CFFT Infrastructure 2014-2015) (PI: Ramsey) CFFT $11,443 Burns' annual direct costs April 1, 2004 - March 31, 2015
Danielle Zerr, MD, MPH
Viral Pathogens and First Time Seizures in the Setting of Illness Private Donation $60,000.00 June 30, 2003
Jane L. Burns, MD
Therapeutic Development Center Microbiology Core Laboratory - #BURNS03Y3 Cystic Fibrosis Foundation Therapeutics $112,315 annual direct costs April 1, 2003 - Dec. 31, 2014
Glen S. Tamura, MD
R29 First Award 1998
Glen S. Tamura, MD
Clinical Investigator Award (K08) 1994
Glen S. Tamura, MD
Children's Health Research Grant 1994
Charles Smith, PhD
Short Term Research Training in Pediatrics for Medical Students unknown $182,260.00 May 1, 1993